Seattle Genetics'' Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
handily beat Wall Street's fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock hit a five-month high. X Analysts were impressed by Seattle Genetics' enthusiasm for its cancer treatment, Padcev. Guidance for full-year sales excluded the likelihood Padcev…#alks #sgen #seattlegenetics #marketsmithcom #svbsecurities #andrewberens #tukysa #astrazeneca #daiichisankyo #rbccapitalmarkets (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2023 Category: Consumer Health News Source Type: news
Opioid Antidote Narcan May Soon Be Sold Over the Counter
WASHINGTON — The overdose-reversing drug naloxone should be made available over the counter to aid the national response to the opioid crisis, U.S. health advisers said Wednesday.
The panel of Food and Drug Administration experts voted unanimously in favor of the switch after a full day of presentations and discussions centered on whether untrained users would be able to safely and effectively use the nasal spray in emergency situations.
The positive vote, which is not binding, came despite concerns from some panel members about the drug’s instructions and packaging, which caused confusion among some people in ...
Source: TIME: Health - February 16, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news
Natco Pharma submits application with USFDA for generic cancer drug
The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 13, 2023 Category: Pharmaceuticals Source Type: news
AstraZeneca: Jeremy Hunt 'disappointed' by drugs firm's low-tax move
AstraZenaca chose Republic of Ireland for £320m factory because of the UK's "discouraging" tax rate. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 10, 2023 Category: Consumer Health News Source Type: news
AstraZeneca: Jeremy Hunt'disappointed' by drugs firm's low tax move
Mr Hunt told the BBC: "We're disappointed that we lost out this time. And we agree with the fundamental case they're making which is that we need our business taxation to be more competitive and we want to bring business taxes down. "But the only tax cuts we won't consider are ones that are funded…#moderna #merck #richardtorbett #astrazeneca #nhs #bbcradio4 (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2023 Category: Consumer Health News Source Type: news
Britain ’s economy shows zero fourth-quarter growth, narrowly avoids recession
Britain’s economy showed zero growth in the final three months of 2022 – enough for it to avoid entering a recession for now – but faces tough prospects in 2023 as households continue to wrestle with double-digit inflation. Monthly gross domestic product data for December – when there were…#rishisunak #jeremyhunt #queenelizabeths #bankofengland #deloitte #debapratimde #boe #ing #jamessmith #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2023 Category: Consumer Health News Source Type: news
Miller-Fisher Syndrome After Oxford/AstraZeneca COVID-19 Vaccine Miller-Fisher Syndrome After Oxford/AstraZeneca COVID-19 Vaccine
Was this patient ' s development of Miller-Fisher syndrome, a variant of Guillain-Barre syndrome, a complication of receiving the Oxford-AstraZeneca COVID-19 vaccination?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Take AstraZeneca ’s warning seriously. The UK is missing out in life sciences
Another day, another warning from the pharmaceutical sector that ministers’ ambitions to make the UK “a life sciences superpower” are in danger of falling flat. The comments from Sir Pascal Soriot, chief executive of AstraZeneca, were different in one important respect, however. He offered a…#pascalsoriot #astrazeneca #warrington #speke #ireland #nhs #cambridge #dameemmawalmsley #soriots #damekatebingham (Source: Reuters: Health)
Source: Reuters: Health - February 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca met CEO Pascal Soriot's $40B revenue goal early. Now, it plans 15 drug launches by 2030
AstraZeneca has delivered on CEO Pascal Soriot’s promise to grow revenues to more than $40 billion by 2023. Now, the chief exec is already mapping out his next goal. | Pascal Soriot’s pledge to boost AstraZeneca’s revenue to more than $40 billion by 2023 has been met early, and the CEO is already…#astrazeneca #pascalsoriots #goal15 (Source: Reuters: Health)
Source: Reuters: Health - February 9, 2023 Category: Consumer Health News Source Type: news
Take AstraZeneca ’s warning seriously. The UK is missing out in life sciences
Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing BritainAnother day, another warning from the pharmaceutical sector that ministers ’ ambitions to make the UK “a life sciences superpower” are in danger of falling flat. The comments from Sir Pascal Soriot, chief executive of AstraZeneca, were different in one important respect, however. He offered a concrete example of how the UK is already losing out as an investment venue .AstraZeneca had wanted to build a new $360m “state-of-the-art” manufacturing plant in the north-west of England near its existing facili...
Source: Guardian Unlimited Science - February 9, 2023 Category: Science Authors: Nils Pratley Tags: Business AstraZeneca GlaxoSmithKline Pharmaceuticals industry UK news Science Source Type: news
AstraZeneca chief says industry should not pay for NHS Covid costs
Pascal Soriot criticises pricing agreement with UK health service (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 9, 2023 Category: Pharmaceuticals Source Type: news
European stocks higher; German consumer price increases slow
Investing.com - European stock markets traded higher Thursday, boosted by a slowing in the growth of German consumer prices while investors digested a flood of quarterly corporate earnings. At 03:55 ET (08:55 GMT), the in Germany traded 1.1% higher, the in France gained 1.2%, while the in the U.K.…#investingcomeuropean #klaasknot #arcelormittal #astrazeneca #turkey #syria (Source: Reuters: Health)
Source: Reuters: Health - February 9, 2023 Category: Consumer Health News Source Type: news
Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3
Roche is ready to wade into the increasingly ferocious fight for the paroxysmal nocturnal hemoglobinuria (PNH) space. | Roche is ready to wade into the increasingly ferocious fight for the paroxysmal nocturnal hemoglobinuria space. The Big Pharma’s subcutaneous contender matched AstraZeneca’s…#roche #bigpharmas #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2023 Category: Consumer Health News Source Type: news
Tezspire Approved for Self-Administration in the U.S. With a New Pre-filled Pen
Now Offers Patients the Choice of Administration at Home or in a Doctor ' s Office
THOUSAND OAKS, Calif., Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 2, 2023 Category: Drugs & Pharmacology Source Type: news
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Now Offers Patients the Choice of Administration at Home or in a Doctor's Office
THOUSAND OAKS, Calif., Feb. 2, 2023 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration ... Biopharmaceuticals, Drug Delivery, FDA Amgen, AstraZeneca, TEZSPIRE, tezepelumab-ekko, asthma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 2, 2023 Category: Pharmaceuticals Source Type: news
